TheTechno Optimist.

Alnylam Pharmaceuticals—Alnylam partners with Inceptive for AI-driven RNAi drug discoveryAmvuttra (vutrisiran)Alnylam Pharmaceuticals—Alnylam reports Q2 2026 revenue of $1.172 billion, with Amvuttra reaching $1.01 billion in quarterly revenueAlnylam Pharmaceuticals—Alnylam unveils 'Alnylam 2030' strategy to expand RNAi beyond rare disease into diabetes, obesity, and neurological disorders

Nucresiran (ALN-TTRsc)

by Alnylam PharmaceuticalsUS

Next-gen RNAi achieving ~95% TTR knockdown. In Phase 3 for ATTR-CM and hATTR-PN.

PilotStage 3 of 5

Phase 3: TRITON-CM (1,750 patients), TRITON-PN ongoing. Launch targets 2028 (PN), 2030 (CM).

Checked 10 Oct0 updates this week

Milestones

Next · TRITON-PN Phase 3 ongoing with rapid enrollment
  1. TRITON-CM Phase 3 enrollment expanded from 1,250 to 1,750 patientsQ1 2026Complete.
  2. TRITON-PN Phase 3 ongoing with rapid enrollmentTarget 2026Current milestone.
  3. Expected TRITON-PN readout and potential hATTR-PN launchTarget 2028Not yet reached.
  4. Expected TRITON-CM readout and potential ATTR-CM launchTarget 2030Not yet reached.

Upcoming

  1. 2026TRITON-PN Phase 3 ongoing with rapid enrollment (next)
  2. 2028Expected TRITON-PN readout and potential hATTR-PN launch
  3. 2028TRITON-PN Phase 3 data presentation and potential regulatory approval
  4. 2030Expected TRITON-CM readout and potential ATTR-CM launch
  5. 2030TRITON-CM Phase 3 data presentation and potential regulatory approval
Primer